Skip to content
Review Open access

Multi-omics-constrained kinetic models quantify pathway rewiring and predict metabolic vulnerabilities in BRCA1-deficient ovarian cancer.

Nov 2026 · Cell Systems · pp. 101781 · 0 citations · 121 references
Medicine

Abstract

Time-resolved, network-wide consequences of cancer metabolic reprogramming remain poorly understood. We built multi-omics-constrained, near-genome-scale kinetic ensembles for isogenic BRCA1 wild-type and BRCA1-mutant ovarian cancer cells. Covering over 2,100 reactions, the ensembles enabled uncertainty-quantified simulations of nutrient, metabolite, and enzyme perturbations. Metabolic control analysis identified 28 enzyme-mediated vulnerabilities; 24 are linked to experimental or approved DrugBank compounds, whereas four lack documented drug associations. Independent DepMap data supported a subset of these candidates. All 28 emerged directly from the mechanistic model structure and multi-omics constraints, with no calibration to known drug targets or cancer-dependency data. Simulations of thymidylate synthase, hexokinase, and triokinase inhibition predicted target- and physiology-specific changes in pathway use, energy metabolism, and a shared ceramide-linked stress response. Mapping predicted enzyme-activity shifts to BRCA1-associated transcription factors suggested regulatory routes underlying differences between the two states. These ensembles provide a reusable framework for time-resolved, mechanistic hypothesis generation across cancers and other diseases. A record of this paper's transparent peer review process is included in the supplemental information.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.